Recent Updates
Recently added Catalysts
NBIX Positive Sentiment Score: 75/100

Neurocrine Biosciences to Host R&D Day on December 16

Key Takeaway: Neurocrine Biosciences will host its 2025 R&D Day on December 16, 2025, in San Diego. The event will focus on the company's R&D transformation and its expanding neuroscience pipeline. A discussion with Dr. John Krystal from Yale University will be featured. The event will be available via live webcast and archived for later access.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurocrine is showcasing its ongoing R&D transformation.
  • The event will feature a discussion with a key opinion leader.
  • The company has a growing neuroscience pipeline.
  • Neurocrine is dedicated to developing life-changing treatments.

Full Press Release Details

SAN DIEGO,Dec. 9, 2025/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego.
Neurocrine management will highlight the Company's ongoing R&D transformation and its growing neuroscience pipeline. The event will also feature a discussion with key opinion leader John Krystal, M.D., Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology at Yale University.
The live webcast can be accessedhereand on Neurocrine Biosciences' website under Investors atwww.neurocrine.com. A replay of the webcast and the supporting R&D Day presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visitneurocrine.com, and follow the company onLinkedIn,XandFacebook. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
SOURCE Neurocrine Biosciences, Inc.

Frequently Asked Questions

When is Neurocrine's R&D Day scheduled?

Neurocrine's R&D Day is scheduled for December 16, 2025.

Who will speak at the R&D Day event?

Dr. John Krystal from Yale University will be featured at the event.

Where can I access the R&D Day webcast?

The webcast can be accessed on Neurocrine's website under the Investors section.

What topics will be covered during the R&D Day?

The event will highlight Neurocrine's R&D transformation and neuroscience pipeline.

Last updated: Dec 9, 2025